Biofourmis closes Series C funding, reels in $100m

The round was led by SoftBank Vision Fund 2, and the company plans to use the funding to accelerate global expansion.

Digital therapeutics provider Biofourmis has completed a $100m Series C financing round led by SoftBank Vision Fund 2, the company said in a press release. Existing investors such as Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI also participated in this round.

The company plans to use the fund for developing, validating and commercialising several released and unreleased digital therapeutic solutions across cardiology, respiratory, oncology and pain management, with a focus on the US and key Asian markets including China and Japan.

With completion of its funding round, the company has also announced a new organisational structure by categorising its therapeutics and health section. The new structure will enable deeper integration with clients and partners and support ongoing innovation, Biofourmis expects.